Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo

Irene L M Reijers, Alexander M Menzies, Marta Lopez-Yurda, Judith M. Versluis, Elisa A. Rozeman, Robyn P.M. Saw, Winan J. van Houdt, Ellen Kapiteijn, Astrid A M van der Veldt, Karijn P.M. Suijkerbuijk, Hanna Eriksson, Geke A.P. Hospers, W. Martin C. Klop, Alejandro Torres Acosta, L. Grijpink-Ongering, Maria Gonzalez, Anja van der Wal, Abrahim Al‐Mamgani, Andrew J. Spillane, Richard A. Scolyer, Bart A. van de Wiel, Alexander C. J. van Akkooi, Georgina V Long, Christian U Blank